FDA Panel Rejects Use Of Eli Lilly and Company Cancer Drug
GAITHERSBURG, Md., March 13 (Reuters) - Advisers to the U.S. Food and Drug Administration recommended on Monday against approving Eli Lilly & Co.'s Gemzar to treat relapsing ovarian cancer, saying stabilizing the disease without boosting overall survival was not enough to win their support.